FGF23 and X-linked dominant hypophosphatemic rickets: In addition, burosumab, a fully humanized FGF23 antibody, was recently approved for treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalcia (TIO) [16, 17].